FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099564616> ?p ?o ?g. }

• W2099564616 endingPage "e3" @default.
• W2099564616 startingPage "e3" @default.
• W2099564616 abstract "Objective The objective of the trial was to evaluate in a pilot setting the safety and efficacy of interleukin-2 (IL-2) therapy when used without concomitant antiretroviral therapy as a treatment for HIV infection. Design and Setting This was a multicentre randomised three-arm trial conducted between September 1998 and March 2001 at three clinical centres in the United Kingdom. Participants Participants were 36 antiretroviral treatment naïve HIV-1-infected patients with baseline CD4 T lymphocyte counts of at least 350 cells/mm3. Interventions Participants were randomly assigned to receive IL-2 at 15 million international units (MIU) per day (12 participants) or 9 MIU/day (12 participants) or no treatment (12 participants). IL-2 was administered by twice-daily subcutaneous injections for five consecutive days every 8 wk. Outcome Measures Primary outcome was the change from baseline CD4 T lymphocyte count at 24 wk. Safety and plasma HIV RNA levels were also monitored every 4 wk through 24 wk. The two IL-2 dose groups were combined for the primary analysis. Results Area under curve (AUC) for change in the mean CD4 T lymphocyte count through 24 wk was 129 cells/mm3 for those assigned IL-2 (both dose groups combined) and 13 cells/mm3 for control participants (95% CI for difference, 51.3–181.2 cells/mm3; p = 0.0009). Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively. There were no significant differences between the IL-2 (0.13 log10 copies/ml) and control (0.09 log10 copies/ml) groups for AUC of change in plasma HIV RNA over the 24-wk period of follow-up (95% CI for difference, −0.17 to 0.26; p = 0.70). Grade 4 and dose-limiting side effects were in keeping with those previously reported for IL-2 therapy. Conclusions In participants with HIV infection and baseline CD4 T lymphocyte counts of at least 350 cells/mm3, intermittent subcutaneous IL-2 without concomitant antiretroviral therapy was well tolerated and produced significant increases in CD4 T lymphocyte counts and did not adversely affect plasma HIV RNA levels. Trial Registration ClinicalTrials.gov NCT00000909" @default.
• W2099564616 created "2016-06-24" @default.
• W2099564616 creator A5008173217 @default.
• W2099564616 creator A5017815904 @default.
• W2099564616 creator A5025372817 @default.
• W2099564616 creator A5027016440 @default.
• W2099564616 creator A5029717530 @default.
• W2099564616 creator A5030905646 @default.
• W2099564616 creator A5031052325 @default.
• W2099564616 creator A5037540979 @default.
• W2099564616 creator A5045532145 @default.
• W2099564616 creator A5047374087 @default.
• W2099564616 creator A5050538872 @default.
• W2099564616 creator A5068358102 @default.
• W2099564616 creator A5073460580 @default.
• W2099564616 creator A5078455366 @default.
• W2099564616 date "2006-05-19" @default.
• W2099564616 modified "2023-09-29" @default.
• W2099564616 title "A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study" @default.
• W2099564616 cites W123672862 @default.
• W2099564616 cites W1969831680 @default.
• W2099564616 cites W1971479443 @default.
• W2099564616 cites W1977074734 @default.
• W2099564616 cites W1984448060 @default.
• W2099564616 cites W1993051112 @default.
• W2099564616 cites W1998660799 @default.
• W2099564616 cites W2013068560 @default.
• W2099564616 cites W2028067695 @default.
• W2099564616 cites W2030870372 @default.
• W2099564616 cites W2039938554 @default.
• W2099564616 cites W2042909000 @default.
• W2099564616 cites W2045837677 @default.
• W2099564616 cites W2055105927 @default.
• W2099564616 cites W2057178907 @default.
• W2099564616 cites W2071606801 @default.
• W2099564616 cites W2076562284 @default.
• W2099564616 cites W2098152992 @default.
• W2099564616 cites W2102059589 @default.
• W2099564616 cites W2125000460 @default.
• W2099564616 cites W2125052178 @default.
• W2099564616 cites W2142577196 @default.
• W2099564616 cites W2143161686 @default.
• W2099564616 cites W2152035740 @default.
• W2099564616 cites W2160488250 @default.
• W2099564616 cites W2161827428 @default.
• W2099564616 cites W2318289184 @default.
• W2099564616 cites W2322984203 @default.
• W2099564616 cites W2916542119 @default.
• W2099564616 cites W4230231216 @default.
• W2099564616 doi "https://doi.org/10.1371/journal.pctr.0010003" @default.
• W2099564616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1488892" @default.
• W2099564616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16871325" @default.
• W2099564616 hasPublicationYear "2006" @default.
• W2099564616 type Work @default.
• W2099564616 sameAs 2099564616 @default.
• W2099564616 citedByCount "20" @default.
• W2099564616 countsByYear W20995646162012 @default.
• W2099564616 crossrefType "journal-article" @default.
• W2099564616 hasAuthorship W2099564616A5008173217 @default.
• W2099564616 hasAuthorship W2099564616A5017815904 @default.
• W2099564616 hasAuthorship W2099564616A5025372817 @default.
• W2099564616 hasAuthorship W2099564616A5027016440 @default.
• W2099564616 hasAuthorship W2099564616A5029717530 @default.
• W2099564616 hasAuthorship W2099564616A5030905646 @default.
• W2099564616 hasAuthorship W2099564616A5031052325 @default.
• W2099564616 hasAuthorship W2099564616A5037540979 @default.
• W2099564616 hasAuthorship W2099564616A5045532145 @default.
• W2099564616 hasAuthorship W2099564616A5047374087 @default.
• W2099564616 hasAuthorship W2099564616A5050538872 @default.
• W2099564616 hasAuthorship W2099564616A5068358102 @default.
• W2099564616 hasAuthorship W2099564616A5073460580 @default.
• W2099564616 hasAuthorship W2099564616A5078455366 @default.
• W2099564616 hasBestOaLocation W20995646161 @default.
• W2099564616 hasConcept C126322002 @default.
• W2099564616 hasConcept C142462285 @default.
• W2099564616 hasConcept C168563851 @default.
• W2099564616 hasConcept C203014093 @default.
• W2099564616 hasConcept C2777761686 @default.
• W2099564616 hasConcept C2779384505 @default.
• W2099564616 hasConcept C2993143319 @default.
• W2099564616 hasConcept C3013748606 @default.
• W2099564616 hasConcept C535046627 @default.
• W2099564616 hasConcept C71924100 @default.
• W2099564616 hasConcept C90924648 @default.
• W2099564616 hasConceptScore W2099564616C126322002 @default.
• W2099564616 hasConceptScore W2099564616C142462285 @default.
• W2099564616 hasConceptScore W2099564616C168563851 @default.
• W2099564616 hasConceptScore W2099564616C203014093 @default.
• W2099564616 hasConceptScore W2099564616C2777761686 @default.
• W2099564616 hasConceptScore W2099564616C2779384505 @default.
• W2099564616 hasConceptScore W2099564616C2993143319 @default.
• W2099564616 hasConceptScore W2099564616C3013748606 @default.
• W2099564616 hasConceptScore W2099564616C535046627 @default.
• W2099564616 hasConceptScore W2099564616C71924100 @default.
• W2099564616 hasConceptScore W2099564616C90924648 @default.
• W2099564616 hasIssue "1" @default.
• W2099564616 hasLocation W20995646161 @default.
• W2099564616 hasLocation W20995646162 @default.

• next